In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $60.00. Rami Katkhuda has
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $60.00. Rami Katkhuda has
“The third quarter of 2024 marked an important milestone for EFX with the first patient dosed in the Phase 3 SYNCHRONY Outcomes study,” said Andrew Cheng, president and CEO. “With
אנדרו צ’נג, הנשיא והמנכ”ל, הצהיר כי הרבעון השלישי של 2024 היה משמעותי עבור EFX כאשר הם החלו במתן המנה הראשונה למטופל במחקר Phase 3 SYNCHRONY Outcomes. עם התקדמות זו, כל
Shares of companies developing therapies for the liver disease metabolic steatohepatitis, or MASH, are rallying after Novo Nordisk (NVO) said its GLP-1 drug semaglutide showed “superior improvement” in treating the
Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Akero Therapeutics (AKRO – Research Report). The associated price target remains the same with $50.00. Ed Arce has